about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsCancer Evolution and the Limits of Predictability in Precision Cancer MedicineThe promise of circulating tumor cell analysis in cancer managementIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingSurveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management.Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop.Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingSETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.Cancer: evolution within a lifetime.Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale.Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic targetAssessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients.Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy.Parallel evolution of tumour subclones mimics diversity between tumours.Classifying the evolutionary and ecological features of neoplasms.Prognostic and predictive markers in metastatic renal cell carcinoma.The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.Acquired resistance to crizotinib from a mutation in CD74-ROS1.Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.Metastasis seeding cells: Lone invaders or mass migrators?Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.Computational optimisation of targeted DNA sequencing for cancer detection.Intratumor heterogeneity: seeing the wood for the trees.Translating Seminoma Genomic Landscapes into Clinical PracticeEfficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center ExperienceUltra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA SequencingCEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoidsCancer (r)evolutionImmunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
P50
Q21183974-51AC04E3-4E40-479E-A82C-553699461D28Q26767415-82D52E29-62E7-4920-9D62-7F7F299C72A0Q27022113-32C0AB9A-5A5E-4755-9678-9352C56C3690Q27860948-CF9450D6-02B6-4886-983C-BFFB18AC4F53Q33952779-6DA5D7EF-6159-48F1-BED5-843AF9EC399AQ34442770-8B2CF532-9EEF-438B-8875-1525EAD50E04Q34464142-CD524126-53EA-4F6B-8694-A5D1B70EC322Q34559389-959D6773-372B-4C35-AE1A-FFA60C931314Q35511862-58115A4C-EFF9-4A81-9EE6-B1321420E67EQ35540073-10C17B6D-4799-426C-A486-79258CD1AE42Q36192083-E523800B-4837-4EA9-8F91-F8B1DFAFE523Q36256943-C645F5BB-9F2B-4A29-A33C-D86C71B5113EQ36320349-CC3C2591-3554-4C98-8119-CE60FFB32F09Q37736084-893FB1E5-F1DE-4959-88A0-8E5821A47786Q37793837-16910CD6-E556-4A30-9D00-242BD474A93CQ38212368-D8F96E53-A499-4461-87A3-FEAF36BD9C32Q38257835-D2BB1809-F9A5-4B1C-B0EF-2055DDE7ABE9Q38305991-1234A440-AEE5-4730-AC84-B57D0E5F3DC5Q39390952-2E6EF5C1-4526-46DC-B5C4-F87FBF18F54BQ39734181-2BBA92FF-053E-42D4-88AD-D12E7155D765Q40268505-2C85911D-EC76-44F0-ADF2-8A31BF5F3C3EQ42937343-7B9A1447-51A2-42F9-966D-FC6571A35285Q44748335-D5163C47-095E-40C0-8619-00FDB3906EFBQ45067426-5205567E-7EB4-4E0D-BA58-369F5972907DQ45890672-224F5F9C-DDF4-4813-9D7B-9C03C244FDDBQ46064083-E4AFE321-F45A-4D31-92EA-D49751D597A5Q46932181-A0B10068-8EAE-4DBB-95E7-D89FB8F3E43EQ47582754-D8EA8C1A-58CA-41E2-B5A5-07707E42996BQ47725386-A40292B4-F7E3-46E3-8E36-61EA586EEDF6Q49546284-6242B854-B5D6-43E0-8C5C-F2E25A9D8F44Q49836611-72C6A94D-BC5E-4D81-8C26-D009C0CE8C91Q50089660-4951E079-B49C-47D7-82B2-870B705AB6CDQ53080459-5831876D-BC38-477B-A9D0-8A1C3B1DCA0FQ53097757-947E79A9-9A3B-4732-A410-7129467D056EQ57997694-E406AB1D-89C2-42FF-84B0-93AEC7A9B3CCQ58604464-F66529AC-6BD2-4FA9-917D-E3065BD6BB59Q58699975-15372FB5-1684-44B7-8369-24DC8984F64DQ64113851-71829011-8F5A-4B45-AC5F-C0092832D763Q89676789-E82E1836-FAE8-4F80-95D4-6D10CFE82DABQ91310551-22EA7BBE-5F0F-4AA6-BF71-16A3BBFFF09A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Gerlinger
@ast
Marco Gerlinger
@en
Marco Gerlinger
@es
Marco Gerlinger
@fr
Marco Gerlinger
@nl
Marco Gerlinger
@sl
type
label
Marco Gerlinger
@ast
Marco Gerlinger
@en
Marco Gerlinger
@es
Marco Gerlinger
@fr
Marco Gerlinger
@nl
Marco Gerlinger
@sl
prefLabel
Marco Gerlinger
@ast
Marco Gerlinger
@en
Marco Gerlinger
@es
Marco Gerlinger
@fr
Marco Gerlinger
@nl
Marco Gerlinger
@sl
P106
P1153
35773179600
P2038
Marco_Gerlinger2
P21
P2798
P31
P496
0000-0003-2719-299X
P569
2000-01-01T00:00:00Z